Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes

Wollert, 1997, Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development, J. Mol. Med., 75, 492, 10.1007/s001090050134 Hirota, 1995, Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice, Proc. Natl. Acad. Sci. USA, 92, 4862, 10.1073/pnas.92.11.4862 Hirota, 1999, Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress, Cell, 97, 189, 10.1016/S0092-8674(00)80729-1 Kuwahara, 2000, Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes, J. Mol. Cell. Cardiol., 32, 1385, 10.1006/jmcc.2000.1177 Kunisada, 1998, Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes, Circulation, 98, 346, 10.1161/01.CIR.98.4.346 Kunisada, 2000, Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy, Proc. Natl. Acad. Sci. USA, 97, 315, 10.1073/pnas.97.1.315 Starr, 1997, A family of cytokine-inducible inhibitors of signalling, Nature, 387, 917, 10.1038/43206 Endo, 1997, A new protein containing a SH2 domain that inhibits JAK kinases, Nature, 387, 921, 10.1038/43213 Naka, 1997, Structure and function of a new STAT-induced STAT inhibitor, Nature, 387, 924, 10.1038/43219 Hamanaka, 2001, Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo, Circ. Res., 88, 727, 10.1161/hh0701.088512 Kodama, 2000, Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy, Am. J. Physiol. Heart Circ. Physiol., 279, H1635, 10.1152/ajpheart.2000.279.4.H1635 Nicol, 2001, Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy, EMBO J., 20, 2757, 10.1093/emboj/20.11.2757 Minami, 1996, STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line, Proc. Natl. Acad. Sci. USA, 93, 3963, 10.1073/pnas.93.9.3963 Yasukawa, 2001, Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways, J Clin Invest, 108, 1459, 10.1172/JCI13939 English, 1999, Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control, J. Biol. Chem., 274, 31588, 10.1074/jbc.274.44.31588 Ueyama, 2000, Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy, J. Mol. Cell. Cardiol., 32, 947, 10.1006/jmcc.2000.1135 Kanegae, 1995, Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase, Nucleic Acids Res., 23, 3816, 10.1093/nar/23.19.3816 Harada, 1997, Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes, Circulation, 96, 3737, 10.1161/01.CIR.96.10.3737 Nakao, 1992, Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides, J. Hypertens., 10, 907 Kuwahara, 1999, Involvement of cardiotrophin-1 in cardiac myocyte–nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro, Circulation, 100, 1116, 10.1161/01.CIR.100.10.1116 Wollert, 1996, Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways, J. Biol. Chem., 271, 9535, 10.1074/jbc.271.16.9535 Alessi, 1995, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem., 270, 27489, 10.1074/jbc.270.46.27489 Kamakura, 1999, Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus, J. Biol. Chem., 274, 26563, 10.1074/jbc.274.37.26563 Railson, 2002, Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes, Cytokine, 17, 243, 10.1006/cyto.2001.1011 Kodama, 1997, Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes, Circ. Res., 81, 656, 10.1161/01.RES.81.5.656 Oh, 1998, Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes, J. Biol. Chem., 273, 9703, 10.1074/jbc.273.16.9703 Mody, 2001, Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway, FEBS Lett, 502, 21, 10.1016/S0014-5793(01)02651-5 Yoshida, 1996, Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders, Proc. Natl. Acad. Sci. USA, 93, 407, 10.1073/pnas.93.1.407 Regan, 2002, Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects, Proc. Natl. Acad. Sci. USA, 99, 9248, 10.1073/pnas.142293999 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N. Engl. J. Med., 316, 1429, 10.1056/NEJM198706043162301 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N. Engl. J. Med., 325, 293, 10.1056/NEJM199108013250501 Swedberg, 1992, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II), N. Engl. J. Med., 327, 678, 10.1056/NEJM199209033271002 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N. Engl. J. Med., 327, 685, 10.1056/NEJM199209033271003